0. Advocacy Graphic






The Voice of Addiction Medicine

 Leading the movement to transform America's addiction treatment infrastructure and expand access to research-validated, results-based care

ASAM's Advocacy Principles

Advocacy Webpage Graphics Teach It
TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma
Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of addiction medicine so that more patients receive high-quality, evidence-based care
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to coordinated, comprehensive care
 
Advocacy Homepage HR 6 Graphic
 




It's time we treat addiction like other chronic diseases 



workshop2

Advocacy Committees & Councils

ASAM's advocacy could not happen if not for the dedicated effort of our members.

0. Find a Policy Statement 1 - cropped

Public Policy Statements

Learn about ASAM's position on current policy issues.

Teamwork - smallest

Coalitions

ASAM is proud to work collaboratively with others to improve the lives of those living with addiction.
0. Advocacy Toolkits

Advocacy Toolkits

ASAM provides toolkits to help you advocate for public policies that advance addiction medicine and promote access to treatment


 
Legislative Tracker Graphic
 



newspapers-3488857_1920B

ASAM Requests Information on Walmart’s Decision-Making Process Regarding Filling Clinicians’ Prescriptions

by | Nov 01, 2019

 

On October 18, ASAM sent a letter to Walmart’s Chief Medical and Analytics Officer, Dr. Thomas Van Gilder, requesting information regarding its algorithm and decision-making process for determining when Walmart pharmacies will no longer fill a clinician’s controlled substances prescriptions. The letter was sent due to various clinicians receiving notifications from Walmart indicating that Walmart pharmacies would no longer fill their prescriptions. The clinicians expressed concern that Walmart’s decision might be in part due to their prescribing of buprenorphine to treat opioid use disorder (OUD).

 

ASAM met with Walmart’s Health and Wellness Compliance Practice on November 8, 2017, to address similar concerns. During that meeting, representatives from ASAM educated Walmart policymakers on the treatment of addiction, as well as prescribing patterns that might appear suspicious, but are in fact medically appropriate for the treatment of OUD. Since that meeting, ASAM has continued to be made aware of Walmart refusing to fill the prescriptions of various clinicians who prescribe buprenorphine to treat OUD. 

 

Read ASAM’s letter to Walmart here